Login to Your Account



Pain Therapeutics, King Tumble On FDA's Remoxy Rejection

By Donna Young


Friday, December 12, 2008
Shares of Pain Therapeutics Inc. plunged 21 percent Thursday after the San Mateo, Calif.-based firm said it received a complete response letter from the FDA for Remoxy, a controlled-release formulation of oxycodone. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription